Cipla USA Inc UPS Supply Chain SOL Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Cipla USA Inc UPS Supply Chain SOL Pharmaceutical Import Records from India — 10 Products, $16.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla USA Inc UPS Supply Chain SOL — Pharmaceutical Importer Profile (2026) | 10 Products, $16.7M Trade | TransData Nexus

Cipla USA Inc UPS Supply Chain SOL

Pharmaceutical Importer · United States · CNS & Psychiatric Focus · $16.7M Total Trade · DGFT Verified

Cipla USA Inc UPS Supply Chain SOL is a pharmaceutical importer based in United States with a total trade value of $16.7M across 10 products in 8 therapeutic categories. Based on 438 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cipla USA Inc UPS Supply Chain SOL sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Cipla USA Inc UPS Supply Chain SOL — Import Portfolio & Supplier Network

Cipla USA Inc UPS Supply Chain SOL import network — 10 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla USA Inc UPS Supply Chain SOL?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$158.9M	10,000	100.0%

Cipla USA Inc UPS Supply Chain SOL sources from 1 verified Indian supplier across 2,687 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cipla USA Inc UPS Supply Chain SOL Import?

Formulation	Value	Ships
Albuterol sulfate inhalation aerosol	$11.4M	235
Diclofenac sodium topical gel, 1%w/w	$5.3M	255
Albuterol sulfate inhalation aerosol 90mcg ndc no. 69097-142-60 anda no.	$4.6M	92
Budesonide inhalation suspension	$3.3M	67
Diclofenac sodium topical gel 1%w/w ndc no.69097-524-44 anda no.	$3.2M	157
Metoprolol succinate extended release	$3.2M	68
Arformoterol tartrate inhalation	$3.0M	83
Diclofenac sodium topical gel, 1%w/w	$2.7M	99
Diclofenac sodium topical gel, 1%w/w	$2.5M	128
Albuterol sulfate inhalation aerosol 90mcg ndc no 69097 142 60 anda no 209959 1 x 200	$2.3M	45
Diclofenac sodium topical gel, 1%w/w ndc no.69097-524-44 anda no.	$2.1M	103
Sertraline tablets, USP 100 MG ndc no.	$1.9M	38
Esomeprazole magnesium for delayed	$1.8M	36
Ipratropium bromide and albuterol	$1.8M	50
Diclofenac sodium topical gel 1 w w ndc no 69097 524 44 anda no	$1.6M	77

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sertraline	CNS & Psychiatric	$5.9M	118	1.1%	6
2	Esomeprazole	Gastrointestinal	$1.9M	38	0.4%	7
3	Magnesium	Vitamins & Supplements	$1.9M	38	0.5%	5
4	Meloxicam	Analgesics & Antipyretics	$1.5M	92	0.8%	5
5	Celecoxib	Analgesics & Antipyretics	$1.4M	34	1.0%	16
6	Budesonide	Respiratory	$1.3M	26	0.7%	4
7	Fenofibrate	Lipid & Metabolism	$1.2M	53	1.6%	14
8	Fosfomycin	Advanced Antibiotics	$1.1M	22	8.5%	2
9	Ipratropium	Respiratory	$258.0K	13	0.5%	15
10	Lenalidomide	Advanced Oncology	$200.0K	4	0.0%	5

Cipla USA Inc UPS Supply Chain SOL imports 10 pharmaceutical products across 8 categories into United States totaling $16.7M.

Cipla USA Inc UPS Supply Chain SOL — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla USA Inc UPS Supply Chain Solutions is a pharmaceutical importer and buyer based in the United States, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a logistics intermediary, facilitating the importation and distribution of pharmaceutical products within the U.S. market. While specific details about its parent company are not publicly disclosed, Cipla USA Inc UPS Supply Chain Solutions collaborates closely with Cipla Limited, a leading Indian pharmaceutical manufacturer, to source a diverse range of pharmaceutical products. This partnership underscores the company's role in enhancing the availability of affordable and high-quality medicines in the U.S.

2Distribution Network

Cipla USA Inc UPS Supply Chain Solutions leverages a robust distribution network to ensure efficient delivery of pharmaceutical products across the United States. The company utilizes UPS's extensive logistics infrastructure, including temperature-controlled facilities, to manage the storage and transportation of sensitive pharmaceutical products. This network enables the company to maintain a consistent supply chain, meeting the demands of various stakeholders in the healthcare sector. While specific warehouse locations are not publicly detailed, the integration with UPS's global logistics capabilities suggests a comprehensive geographic coverage within the U.S. and potentially beyond.

3Industry Role

In the U.S. pharmaceutical supply chain, Cipla USA Inc UPS Supply Chain Solutions functions primarily as a logistics intermediary. By importing finished pharmaceutical formulations from India, the company plays a crucial role in bridging the gap between Indian manufacturers and the U.S. market. This position allows the company to facilitate the availability of a wide array of pharmaceutical products, contributing to the diversity and affordability of medicines accessible to U.S. consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla USA Inc UPS Supply Chain SOL

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla USA Inc UPS Supply Chain Solutions demonstrates a high degree of sourcing concentration, importing 75.8% of its products from a single supplier, Cipla Limited. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and leverage the established reputation and capabilities of Cipla Limited. The stability of this relationship is evidenced by the consistent volume of shipments over the years, suggesting a reliable and ongoing partnership. However, such concentration also exposes the company to potential risks associated with supply chain disruptions from a single supplier.

2Supply Chain Resilience

The resilience of Cipla USA Inc UPS Supply Chain Solutions' supply chain is closely tied to its exclusive partnership with Cipla Limited. This singular supplier relationship may limit the company's ability to diversify its sourcing options, potentially impacting its capacity to adapt to supply chain disruptions. Additionally, the reliance on a single supplier necessitates a thorough assessment of Cipla Limited's manufacturing practices, regulatory compliance, and operational stability to ensure uninterrupted supply.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports, ensuring that all imported drugs meet standards for quality, safety, and effectiveness. Pharmaceutical companies must adhere to FDA regulations, including facility registration, drug listing, and compliance with labeling requirements, to legally market their products in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. mandate that foreign manufacturers register their establishments with the FDA and list all their drug products intended for U.S. distribution. Additionally, imported drugs must comply with Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal mutual recognition agreement with the European Union, it acknowledges GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Therefore, Indian exporters holding GMP certifications from these organizations are generally considered to meet FDA standards.

Cipla USA Inc UPS Supply Chain SOL — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla USA Inc UPS Supply Chain Solutions focuses on importing pharmaceutical products across various therapeutic categories, with a significant emphasis on Central Nervous System (CNS) & Psychiatric, Analgesics & Antipyretics, and Gastrointestinal medications. This strategic focus aligns with the growing demand for treatments in these areas within the U.S. market. The company's product portfolio, which includes medications like Sertraline, Esomeprazole, and Meloxicam, addresses prevalent health conditions, thereby meeting critical patient needs.

2Sourcing Profile

The company's sourcing strategy is centered on importing generic drug formulations from India, leveraging the country's robust pharmaceutical manufacturing capabilities. By focusing on finished pharmaceutical formulations, Cipla USA Inc UPS Supply Chain Solutions ensures a consistent supply of high-quality medications that are ready for distribution, thereby streamlining the procurement process and reducing lead times.

3Market Positioning

Based on its product mix, Cipla USA Inc UPS Supply Chain Solutions serves a diverse segment of the U.S. pharmaceutical market, including retail pharmacies, hospitals, and wholesale distributors. The company's focus on essential therapeutic areas positions it to meet the needs of various healthcare providers, ensuring that patients have access to necessary medications across different healthcare settings.

Seller's Guide — How to Become a Supplier to Cipla USA Inc UPS Supply Chain SOL

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Cipla USA Inc UPS Supply Chain Solutions, especially if they can demonstrate compliance with FDA regulations and offer high-quality pharmaceutical formulations. Potential gaps in the company's current sourcing include the need for diversification in supplier relationships and the introduction of new therapeutic products to meet evolving market demands.

2Requirements & Qualifications

Indian exporters seeking to supply Cipla USA Inc UPS Supply Chain Solutions and the U.S. market must obtain FDA registration for their manufacturing facilities and list all drug products intended for export. Additionally, holding GMP certifications from recognized international bodies such as WHO or PIC/S is essential. Compliance with FDA labeling requirements, including providing accurate and truthful information in English, is also mandatory.

3How to Approach

Indian exporters should initiate the relationship by ensuring full compliance with FDA regulations, including facility registration and GMP certification. Participating in tenders and responding to requests for proposals from Cipla USA Inc UPS Supply Chain Solutions can provide opportunities for collaboration. Developing a comprehensive regulatory filing strategy that addresses FDA requirements and establishing clear communication channels will facilitate a successful partnership. Understanding the FDA's import procedures and maintaining consistent product quality are crucial for meeting Cipla USA Inc UPS Supply Chain Solutions' expectations.

Frequently Asked Questions — Cipla USA Inc UPS Supply Chain SOL

What products does Cipla USA Inc UPS Supply Chain SOL import from India?

Cipla USA Inc UPS Supply Chain SOL imports 10 pharmaceutical products across 8 categories. Top imports: Sertraline ($5.9M), Esomeprazole ($1.9M), Magnesium ($1.9M), Meloxicam ($1.5M), Celecoxib ($1.4M).

Who supplies pharmaceuticals to Cipla USA Inc UPS Supply Chain SOL from India?

Cipla USA Inc UPS Supply Chain SOL sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $158.9M).

What is Cipla USA Inc UPS Supply Chain SOL's total pharmaceutical import value?

Cipla USA Inc UPS Supply Chain SOL's total pharmaceutical import value from India is $16.7M, based on 438 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla USA Inc UPS Supply Chain SOL focus on?

Cipla USA Inc UPS Supply Chain SOL imports across 8 categories. The largest: CNS & Psychiatric (35.4%), Analgesics & Antipyretics (17.5%), Gastrointestinal (11.4%).

Get Full Cipla USA Inc UPS Supply Chain SOL Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.